Summary LAVA is able to form a highly profitable partnership with Seagen to develop LAVA-1223 for various solid tumors. The company's Gammabody platform holds strong promises as a delivery vehicle for a differentiated type of cellular therapy. There is an upcoming data release...
June 16 (UPI) -- The 100-plus carat Juno diamond was auctioned Thursday in New York by Sotheby's, bringing in over $12.9 million. The Earth Star, an orange-brown diamond of 111.59 carats, was expected to bring as much as $2.5 million. The Juno diamond is a 101.41 carat pear-shap...
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli analyzes Gilead 's (NASDAQ: GILD) earnings report and discusses why the biotech giant could see fairly low revenue growth or even see earnings dr...
It does mean that a company with research centered around each of these divisions, like a cluster of trees each growing additional branches from its own trunk, will usually do much better than a company working on a number of unrelated new products which, if successful, will land it in sev...
Introduction We present here some results of a study on U.S. listed companies in the healthcare sector (Nasdaq, NYSE and Amex) based on their patent activity based on PCT (Patent Cooperation Treaty) patent applications administered by the World Intellectual Property Office (WIPO). We have sh...
News, Short Squeeze, Breakout and More Instantly...
Juno Therapeutics Inc. Company Name:
JUNO Stock Symbol:
NASDAQ Market:
Juno Therapeutics Inc. Website:
June 16 (UPI) -- The 100-plus carat Juno diamond was auctioned Thursday in New York by Sotheby's, bringing in over $12.9 million. The Earth Star, an orange-brown diamond of 111.59 carats, was expected to bring as much as $2.5 million. The Juno diamond is a 101.41 carat pear-shap...
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli analyzes Gilead 's (NASDAQ: GILD) earnings report and discusses why the biotech giant could see fairly low revenue growth or even see earnings dr...